RxDoctor Payments Data

Jose Burgos, MD

Internal Medicine · El Paso, TXNPI 1245437425

Payments from drug & device makers

$3,879in general payments, 2019–2025

Across 203 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$654
  • Novartis$593
  • Johnson & Johnson$251
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$251
  • Pfizer$239
  • plus $804 from 12 others

What the payments were for

  • Food & beverage$3,85999%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,879 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$447,850
Medicare patients
812
Services billed
3,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban691$202,434
XifaxanRifaximin52$83,243
BiktarvyBictegrav/Emtricit/Tenofov Ala20$56,443
JardianceEmpagliflozin70$20,632
OzempicSemaglutide18$18,973
RexultiBrexpiprazole16$15,976
XareltoRivaroxaban57$15,800
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,757
EntrestoSacubitril/Valsartan63$11,729
SantylCollagenase Clostridium Hist.33$10,851
Lantus SolostarInsulin Glargine,hum.Rec.Anlog144$8,846
GemtesaVibegron37$8,792
JanuviaSitagliptin Phosphate19$8,194
Megestrol Acetate61$7,933
Memantine Hcl304$7,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$239$202,434691 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$251$83,24352 claims
Boehringer IngelheimJardiance$15$20,63270 claims
Otsuka America Pharmaceutical, Inc.Rexulti$119$15,97616 claims
Johnson & JohnsonXarelto$251$15,80057 claims
NovartisEntresto$593$11,72963 claims
AstraZenecaLokelma, Farxiga$1,086$10,79838 claims
Astellas Pharma US IncMyrbetriq$93$4,90125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →